Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people stay on 0.25mg Wegovy for four weeks. That single month is a deliberate settling-in period, not the dose where weight loss begins in earnest. The 0.25mg starting dose exists to give your body time to adjust to semaglutide before the therapeutic doses kick in — your prescriber will then move you up through the schedule. These are prescription-only medicines; a clinician assesses your suitability before any treatment starts.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
A question our prescribers hear fairly regularly goes something like: "Can I just skip the starter dose and begin at something stronger?" It is an understandable impulse, you want results, and 0.25mg of Wegovy is not where those results live. But the premise of the question gets things backwards.
The 0.25mg dose is not a watered-down version of the treatment. It is a physiological on-boarding step, specifically designed so that your digestive system can adapt to semaglutide's effects before exposure increases. Semaglutide slows gastric emptying and acts on appetite centres in the brain via GLP-1 receptors. Introduce too much of that activity too quickly and the nausea, vomiting and digestive discomfort that are the most common early side effects become far harder to tolerate. Starting low and moving gradually is not timid, it is how the medicine is designed to be used. The NHS patient information on semaglutide sets out the full schedule and explains why the titration steps exist.
Four weeks at 0.25mg is typically the standard. Most patients then move to 0.5mg, and the step-up pattern continues from there. If your body is still adjusting (or if life is complicated that month, say around a holiday or an unusually disruptive few weeks) your prescriber can keep you at 0.25mg for longer. That is a clinical call, not a delay. You can read more about whether it is safe to remain at 0.25mg if your situation warrants a slower approach.
Four weeks sounds clean on paper. In practice it is worth thinking about when your first pen arrives relative to your next expected order. If you order mid-month and your four weeks at 0.25mg ends on a Thursday, your next prescription review and dispatch follows that same cadence. Timing your first order so the step-up lands at a predictable point (the start of a month, after a planned trip) is just practical planning, not overthinking it.
During those four weeks, the honest expectation is modest. Some people notice appetite changes fairly quickly; others feel little at 0.25mg and only begin to notice effects once the dose climbs. Either experience is normal. The half-life of 0.25mg semaglutide in your system is roughly a week, which is why weekly injections maintain stable blood levels even at this introductory level.
Weight loss data from the STEP 1 trial, published in the New England Journal of Medicine, tracked participants over 68 weeks up to the 2.4mg maintenance dose, average reduction of around 15% of body weight. That outcome is built across the entire schedule, not front-loaded into the early weeks. Being at 0.25mg is not wasted time; it is laying the groundwork. For a full picture of how long each Wegovy dose lasts through the schedule, that page maps every step.
The four-week standard is not a rule so rigid that no one deviates from it. A prescriber may recommend staying at 0.25mg for longer if nausea or vomiting has been meaningful enough to interfere with daily life, if there are other health factors worth monitoring before stepping up, or simply if you have asked for a slower approach and that is clinically appropriate for you.
There is no published evidence that spending six or eight weeks at the starting dose harms outcomes. What it does is delay arrival at the therapeutic doses where weight loss becomes more significant. The decision is always individual. If you are unsure what your own timeline should look like, that is precisely the conversation to have with your prescriber rather than adjusting anything independently. A look at the full Wegovy dose structure can help you understand where you are in the journey and what comes next, and if you are wondering how long you stay on 0.5mg Wegovy once you get there, that page walks through what to expect at that next stage. Cost across the months of titration is something many people reasonably wonder about, what Wegovy costs in the UK covers the private market context honestly.
At nume, a real clinician reviews every consultation and every repeat request before any prescription is issued. There is no algorithm deciding when you step up. If your experience at 0.25mg has been uncomfortable, say so at your review, that information shapes what happens next. You can also find answers to common questions on our FAQs page or reach us directly through our contact page. When you are ready to take the next step, speak to our prescribers about starting your assessment.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.